KR20230035311A - Nek7 키나제의 억제제 - Google Patents

Nek7 키나제의 억제제 Download PDF

Info

Publication number
KR20230035311A
KR20230035311A KR1020237000263A KR20237000263A KR20230035311A KR 20230035311 A KR20230035311 A KR 20230035311A KR 1020237000263 A KR1020237000263 A KR 1020237000263A KR 20237000263 A KR20237000263 A KR 20237000263A KR 20230035311 A KR20230035311 A KR 20230035311A
Authority
KR
South Korea
Prior art keywords
compound
pyrazolo
mmol
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237000263A
Other languages
English (en)
Korean (ko)
Inventor
데이비드 제임스 베어스
3세 존 사이 케옹 카우웨
알렉시스 헨리 아벨 몰라드
Original Assignee
할리아 테라퓨틱스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 할리아 테라퓨틱스, 인코포레이티드 filed Critical 할리아 테라퓨틱스, 인코포레이티드
Publication of KR20230035311A publication Critical patent/KR20230035311A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Epidemiology (AREA)
KR1020237000263A 2020-06-08 2021-06-08 Nek7 키나제의 억제제 Pending KR20230035311A (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063036244P 2020-06-08 2020-06-08
US63/036,244 2020-06-08
US202163170776P 2021-04-05 2021-04-05
US63/170,776 2021-04-05
US202163185257P 2021-05-06 2021-05-06
US63/185,257 2021-05-06
PCT/US2021/036398 WO2021252488A1 (en) 2020-06-08 2021-06-08 Inhibitors of nek7 kinase

Publications (1)

Publication Number Publication Date
KR20230035311A true KR20230035311A (ko) 2023-03-13

Family

ID=76731040

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000263A Pending KR20230035311A (ko) 2020-06-08 2021-06-08 Nek7 키나제의 억제제

Country Status (13)

Country Link
US (1) US20230203045A1 (https=)
EP (1) EP4161933A1 (https=)
JP (1) JP2023528659A (https=)
KR (1) KR20230035311A (https=)
CN (1) CN116075513A (https=)
AU (1) AU2021289345A1 (https=)
BR (1) BR112022025012A2 (https=)
CA (1) CA3186041A1 (https=)
CO (1) CO2022019131A2 (https=)
IL (1) IL298849A (https=)
MX (1) MX2022015495A (https=)
TW (1) TWI908811B (https=)
WO (1) WO2021252488A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS65962B1 (sr) 2020-05-08 2024-10-31 Halia Therapeutics Inc Inhibitori nek7 kinaze
US20240400551A1 (en) * 2021-01-25 2024-12-05 Halia Therapeutics, Inc. Nek7 inhibitors
US20240158394A1 (en) * 2022-09-14 2024-05-16 Halia Therapeutics, Inc. Nek7 inhibitors
WO2025140570A1 (zh) * 2023-12-29 2025-07-03 北京普祺医药科技股份有限公司 一种nek7抑制剂、药物组合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US20110189167A1 (en) 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
EP2802212B1 (en) 2012-01-12 2015-12-30 Basf Se Herbicidal isoxazolo[5,4-b]pyridines
CN105017256A (zh) 2014-04-29 2015-11-04 浙江导明医药科技有限公司 多氟化合物作为布鲁顿酪氨酸激酶抑制剂
RU2724345C2 (ru) 2015-10-09 2020-06-23 Галапагос Нв N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ
CN108250200A (zh) 2016-12-28 2018-07-06 中国科学院上海药物研究所 一种具有Axl抑制活性的化合物及其制备和应用
DE102017200543A1 (de) 2017-01-13 2018-07-19 Baden-Württemberg Stiftung Ggmbh Verfahren zur Behandlung einer Oberfläche eines Hartmetallkörpers und zur Beschichtung des behandelten Hartmetallkörpers mit einer Diamantschicht
DE102017118230B4 (de) * 2017-08-10 2021-04-22 Christoph Lucks Verfahren zur Analyse und/oder Überwachung von Brücken sowie entsprechendes System und entsprechende Verwendung
MX2020001776A (es) * 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
IL277408B2 (en) * 2018-04-05 2024-08-01 Merck Patent Gmbh Heteroaryl compounds as IRAK type II inhibitors and their use
AR118119A1 (es) 2019-02-18 2021-09-22 Genentech Inc Compuestos de pirido-pirimidinilo y métodos de uso
CN111646995B (zh) * 2019-03-04 2023-03-21 四川大学 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途
WO2021057877A1 (zh) * 2019-09-26 2021-04-01 深圳市塔吉瑞生物医药有限公司 取代的芳香稠合环衍生物及其组合物及用途
AU2020436612A1 (en) * 2020-03-16 2022-09-01 Flash Therapeutics, Llc Compounds for treating or inhibiting recurrence of acute myeloid leukemia

Also Published As

Publication number Publication date
BR112022025012A2 (pt) 2023-02-14
CN116075513A (zh) 2023-05-05
US20230203045A1 (en) 2023-06-29
IL298849A (en) 2023-02-01
CO2022019131A2 (es) 2023-03-07
WO2021252488A1 (en) 2021-12-16
CA3186041A1 (en) 2021-12-16
JP2023528659A (ja) 2023-07-05
TW202208368A (zh) 2022-03-01
EP4161933A1 (en) 2023-04-12
AU2021289345A1 (en) 2023-01-19
MX2022015495A (es) 2023-03-14
TWI908811B (zh) 2025-12-21

Similar Documents

Publication Publication Date Title
US12091413B2 (en) Inhibitors of NEK7 kinase
TWI908811B (zh) Nek7激酶抑制劑
WO2022216680A1 (en) Nek7 inhibitors
WO2022159835A1 (en) Nek7 inhibitors
WO2024059200A1 (en) Nek7 inhibitors
US20250177382A1 (en) Nek7 inhibitors
RU2848120C1 (ru) Ингибиторы киназы nek7
RU2860767C2 (ru) Ингибиторы nek7
RU2848134C1 (ru) Ингибиторы киназы nek7
US20250388571A1 (en) Amp-activated protein kinase modulator compounds and uses thereof
WO2023049270A1 (en) Pyrrole[2,3-b]pyridine derivatives as tyro3 inhibitors
WO2023064218A1 (en) Tyro3 inhibitors
HK40088615B (en) Inhibitors of nek7 kinase
HK40088615A (en) Inhibitors of nek7 kinase

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000